Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Treatment with con-G showed improved neurological scoring and decreased peri-infarct Ca²⁺ microdeposits. by Rashna Balsara (714796)

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

A: Top, representative recording of the application, for 10 seconds, of different concentrations of tribendimidine which produces a depolarization (upward movement of the thickest... by Alan P. Robertson (362793)

Estimates of BMI category coefficients to predict the mean increase or decrease in postoperative OKS. by Jonathan Thomas Evans (9322437)

Mean amount of cells per staining in % extracted from Fig 3. by Célia Dos Santos (306471)

Reduced RabGEF1 expression decreases NGF-induced TrkA phosphorylation but not TrkA internalization. by See-Ying Tam (828866)

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

“…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [³H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”

Mean of the electrocardiographic intervals during the treatment. by Thaysa de Sousa Reis (19338663)

Mean of the electrocardiographic intervals during the recovery. by Thaysa de Sousa Reis (19338663)

Mean decrease in accuracy for candidate variables. by Maogui Hu (319021)

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

CONSORT flow diagram. by Judith I. Tsui (5983160)

Adverse events in placebo arm. by Judith I. Tsui (5983160)